WilmerHale Advises Autobahn Labs in Drug Discovery Collaboration with UCSF

WilmerHale Advises Autobahn Labs in Drug Discovery Collaboration with UCSF

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

On December 21, 2020, Autobahn Labs, a virtual incubator partnering with top academic and research institutions to catalyze early-stage drug discovery and development, announced a strategic collaboration with the University of California San Francisco (UCSF). The organizations will partner to identify promising early science with significant therapeutic potential, forming jointly owned ventures to accelerate the translation of scientific ideas to novel therapeutics. The collaboration with UCSF is the second partnership announced by Autobahn Labs since the organization’s launch in June 2020, and expands the reach of the innovative partnership between Samsara BioCapital and Evotec.

The WilmerHale team representing Autobahn Labs includes Jason Kropp, Jenna Ventorino and Ryan Crane.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel